On this page
MVK
mevalonate kinase
The MVK gene provides instructions for the mevalonate kinase enzyme, crucial for the mevalonate pathway, which is involved in cholesterol synthesis and the production of other essential cellular molecules. The MVK gene is central to cellular metabolism, encoding an enzyme that facilitates a key step in the biosynthesis of cholesterol and isoprenoids.
MVK is located on the long (q) arm of chromosome 12, at band 12q24.11. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 12 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The MVK gene encodes the mevalonate kinase enzyme, a vital component of the mevalonate pathway. This pathway is fundamental for synthesising cholesterol, steroid hormones, and bile acids, as well as isoprenoids which are necessary for various cellular functions, including cell growth and differentiation. Pathogenic variants in the MVK gene can disrupt this pathway, leading to specific inherited conditions.
What the gene does
The mevalonate kinase enzyme, produced from the MVK gene, plays a critical role in the mevalonate pathway. Specifically, it catalyses the conversion of mevalonic acid to mevalonate-5-phosphate. This conversion is the second step in a multi-stage process that ultimately leads to the production of cholesterol. Cholesterol is a precursor for steroid hormones, important for development and reproduction, and bile acids, essential for fat digestion. Beyond cholesterol, the mevalonate pathway also generates isoprenoids, which are vital for several cellular activities, including maintaining the cell's structural framework, regulating gene activity, and facilitating protein production and modification.
Video: Genetics 101
Chromosome location
The MVK gene is situated on chromosome 12 at position 12q24.11. This specific genomic location helps in mapping and understanding the gene's position within the human genome and its proximity to other genes.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein.
Key variants
Variants within the MVK gene can alter the function of the mevalonate kinase enzyme. These genetic changes can range from single nucleotide substitutions to larger deletions or insertions, potentially affecting the enzyme's stability, activity, or expression. Pathogenic variants are inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the altered gene to develop a related condition.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1126G>A | p.Gly376Ser | Pathogenic/Likely pathogenic | ★★☆☆ | Mevalonic aciduria |
c.207_208del | p.Leu70fs | Pathogenic | ★★☆☆ | Mevalonic aciduria |
c.349_350del | p.Leu117fs | Pathogenic/Likely pathogenic | ★★☆☆ | MVK-related disorder |
c.3G>A | p.Met1Ile | Pathogenic/Likely pathogenic | ★★☆☆ | Mevalonic aciduria |
c.560_561del | p.Lys187fs | Pathogenic | ★★☆☆ | MVK-related disorder |
c.58C>A | p.His20Asn | Pathogenic | ★★☆☆ | Mevalonic aciduria |
c.605dup | p.Val203fs | Pathogenic/Likely pathogenic | ★★☆☆ | MVK-related disorder |
c.643C>T | p.Arg215Ter | Pathogenic | ★★☆☆ | Mevalonic aciduria |
c.790dup | p.Leu264fs | Pathogenic | ★★☆☆ | Mevalonic aciduria |
c.830G>A | p.Arg277His | Pathogenic/Likely pathogenic | ★★☆☆ | Autoinflammatory syndrome |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the MVK gene are primarily associated with Mevalonate kinase deficiency. This condition presents with a spectrum of severity, with the less severe form known as hyperimmunoglobulinemia D syndrome (HIDS) and the more severe form referred to as mevalonic aciduria (MVA). Both are characterised by disrupted mevalonate pathway function due to impaired mevalonate kinase enzyme activity.
Inheritance pattern
Conditions caused by pathogenic MVK variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
The MVK gene is included in several NHS Genomic Medicine Service national test panels within the UK. It is categorised as 'green' for conditions such as Autoinflammatory disorders (R413), Cholestasis (R171), Likely inborn error of metabolism (R98), Periodic fever syndromes, and Primary immunodeficiency or monogenic inflammatory bowel disease (R15). This indicates that there is strong evidence for the gene's association with these conditions, supporting its use in diagnostic testing in these contexts.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the role of the MVK gene?
The MVK gene provides instructions for making the mevalonate kinase enzyme, which is essential for the mevalonate pathway. This pathway produces cholesterol, steroid hormones, bile acids, and other molecules vital for cell growth, differentiation, and overall cellular function.
What conditions are associated with MVK gene variants?
Variants in the MVK gene are associated with Mevalonate kinase deficiency. This condition has two main forms: the less severe hyperimmunoglobulinemia D syndrome (HIDS) and the more severe mevalonic aciduria (MVA).
How are MVK gene variants inherited?
Pathogenic MVK gene variants are inherited in an autosomal recessive manner. This means an individual must inherit two copies of a pathogenic variant, one from each parent, to develop a condition associated with this gene.
References
- Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clinical biochemistry. 2007. PMID: 17467679
- Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet journal of rare diseases. 2006. PMID: 16722536
- Mandey SH, Schneiders MS, Koster J. Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Human mutation. 2006. PMID: 16835861